A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.

Journal: Indian journal of cancer

PMID: 30082554

Abstract

INTRODUCTION: The present study for biosimilar trastuzumab was a multicentric, randomized, two-arm parallel-group, comparative phase III study in patients with metastatic breast cancer.

Authors

Prasad Apsangikar

Medical Affairs Group, Reliance Life Sciences, Navi Mumbai, Maharashtra, India.
Sunil Chaudhry

Medical Affairs Group, Reliance Life Sciences, Navi Mumbai, Maharashtra, India.
Manoj Naik

Medical Affairs Group, Reliance Life Sciences, Navi Mumbai, Maharashtra, India.
Shashank Deoghare

Clinical Research Group, Reliance Life Sciences, Navi Mumbai, Maharashtra, India.
Jamila Joseph

Clinical Research Group, Reliance Life Sciences, Navi Mumbai, Maharashtra, India.

Keywords

Adult Aged Antineoplastic Combined Chemotherapy Protocols Biosimilar Pharmaceuticals Breast Neoplasms Disease-Free Survival Drug-Related Side Effects and Adverse Reactions Female Humans India Middle Aged Paclitaxel Receptor, ErbB-2 Remission Induction Trastuzumab

External Resources

View on PubMed Access via DOI PubMed (30082554)

A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals